Skip to main content
Erschienen in: CEN Case Reports 1/2020

14.09.2019 | Case Report

Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis

verfasst von: Naoya Toriu, Naoki Sawa, Rikako Hiramatsu, Hiroki Mizuno, Daisuke Ikuma, Akinari Sekine, Noriko Hayami, Keiichi Sumida, Masayuki Yamanouchi, Eiko Hasegawa, Junichi Hoshino, Kenmei Takaichi, Atsushi Wake, Kenichi Ohashi, Takeshi Fujii, Yoshifumi Ubara

Erschienen in: CEN Case Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

We report a 58-year-old Japanese woman who presented with nephrotic syndrome. Steroid therapy and cyclosporine A administration were initiated, but hematological remission and renal response were not achieved. Renal biopsy revealed amyloid deposits in the mesangial region and the small arteries. Proteomic analysis based on laser microdissection and mass spectrometry showed that the amyloid deposits were composed of the constant region of the lambda light chain. She received vincristine, adriamycin, and dexamethasone therapy followed by high-dose melphalan and autologous stem cell transplantation, resulting in hematological complete remission and renal response with negative urinary Bence-Jones protein and proteinuria. Renal biopsy was performed four times during follow-up, demonstrating that amyloid deposits decreased gradually, while glomeruli showing global sclerosis increased from 3 to 62%. This case suggests that glomerular amyloid deposits can be cleared via tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated cells after stem cell transplantation.
Literatur
1.
Zurück zum Zitat Milani P, et al. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1):e2018022.CrossRef Milani P, et al. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1):e2018022.CrossRef
2.
Zurück zum Zitat Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17(12):3458–71.CrossRef Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17(12):3458–71.CrossRef
3.
Zurück zum Zitat Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–23.CrossRef Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–23.CrossRef
4.
Zurück zum Zitat Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis. BMC Nephrol. 2012;13:118.CrossRef Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis. BMC Nephrol. 2012;13:118.CrossRef
5.
Zurück zum Zitat Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet (London, England). 2016;387(10038):2641–54.CrossRef Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet (London, England). 2016;387(10038):2641–54.CrossRef
6.
Zurück zum Zitat Nasr SH, Said SM, Valeri AM, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83(3):463–70.CrossRef Nasr SH, Said SM, Valeri AM, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83(3):463–70.CrossRef
7.
Zurück zum Zitat Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42(1):72–7.CrossRef Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42(1):72–7.CrossRef
8.
Zurück zum Zitat Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127(5):543–51.CrossRef Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127(5):543–51.CrossRef
9.
Zurück zum Zitat Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEJM. 2007;357(11):1083–93.CrossRef Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEJM. 2007;357(11):1083–93.CrossRef
10.
Zurück zum Zitat Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010;5(12):2180–7.CrossRef Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010;5(12):2180–7.CrossRef
11.
Zurück zum Zitat Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346–52.CrossRef Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346–52.CrossRef
12.
Zurück zum Zitat Milani P, Merlini G, Palladini G. Novel therapies in light chain amyloidosis. Kidney Int Rep. 2018;3(3):530–41.CrossRef Milani P, Merlini G, Palladini G. Novel therapies in light chain amyloidosis. Kidney Int Rep. 2018;3(3):530–41.CrossRef
13.
Zurück zum Zitat Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax. 1999;54(5):444–51.CrossRef Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax. 1999;54(5):444–51.CrossRef
14.
Zurück zum Zitat Katoh N, Matsuda M, Tsuchiya-Suzuki A, et al. Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies. Br J Haematol. 2011;153(4):535–8.CrossRef Katoh N, Matsuda M, Tsuchiya-Suzuki A, et al. Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies. Br J Haematol. 2011;153(4):535–8.CrossRef
15.
Zurück zum Zitat Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial expansion. Kidney Int. 1994;45(2):328–35.CrossRef Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial expansion. Kidney Int. 1994;45(2):328–35.CrossRef
16.
Zurück zum Zitat Yamazaki O, Ubara Y, Suwabe T, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. J Clin Exp Nephrol. 2009;13(5):522–5.CrossRef Yamazaki O, Ubara Y, Suwabe T, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. J Clin Exp Nephrol. 2009;13(5):522–5.CrossRef
17.
Zurück zum Zitat Iwadate D, Hasegawa E, Hoshino J, et al. The long-term outcomes after VAD plus SCT therapy in a patient with AL amyloidosis and severe factor X deficiency. Intern Med. 2018;57(5):701–6.CrossRef Iwadate D, Hasegawa E, Hoshino J, et al. The long-term outcomes after VAD plus SCT therapy in a patient with AL amyloidosis and severe factor X deficiency. Intern Med. 2018;57(5):701–6.CrossRef
18.
Zurück zum Zitat Nakayama M, Kashiwagi M, Katafuchi R, et al. Resolution of primary amyloidosis by melphalan and prednisolone: a case report. Clin Nephrol. 2005;63(3):215–20.CrossRef Nakayama M, Kashiwagi M, Katafuchi R, et al. Resolution of primary amyloidosis by melphalan and prednisolone: a case report. Clin Nephrol. 2005;63(3):215–20.CrossRef
Metadaten
Titel
Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis
verfasst von
Naoya Toriu
Naoki Sawa
Rikako Hiramatsu
Hiroki Mizuno
Daisuke Ikuma
Akinari Sekine
Noriko Hayami
Keiichi Sumida
Masayuki Yamanouchi
Eiko Hasegawa
Junichi Hoshino
Kenmei Takaichi
Atsushi Wake
Kenichi Ohashi
Takeshi Fujii
Yoshifumi Ubara
Publikationsdatum
14.09.2019
Verlag
Springer Singapore
Erschienen in
CEN Case Reports / Ausgabe 1/2020
Elektronische ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-019-00416-1

Weitere Artikel der Ausgabe 1/2020

CEN Case Reports 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.